820 filings
Page 3 of 41
NT 10-Q
t4o74txahf0
14 Aug 23
Notice of late quarterly filing
4:09pm
ARS
meze rj6x
7 Aug 23
Annual report to shareholders
4:09pm
DEFA14A
7oyo 8b9azb780c
7 Aug 23
Additional proxy soliciting materials
4:07pm
8-K
o1p1fyy sl
7 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
mk4ltxt
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
awga3g1ty0w627
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
qfw4rff
9 May 23
Soligenix Announces Pricing of $8.5 Million Public Offering
4:15pm
EFFECT
9p7pbazx1tgqirfl8f
8 May 23
Notice of effectiveness
12:15am
424B4
qx95jjiluaugja6 dfj
5 May 23
Prospectus supplement with pricing info
6:43pm
CORRESP
fsfdvjv6lyu7ac
4 May 23
Correspondence with SEC
12:00am
8-K
pov5ig 1tn0k6
3 May 23
Strengthens regulatory and orphan drug development expertise
5:00pm
8-K
hzgzf mqsxei
1 May 23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
7:45am
8-K
e24rsjskn09
19 Apr 23
Entry into a Material Definitive Agreement
5:25pm
CORRESP
i9svb
19 Apr 23
Correspondence with SEC
12:00am
8-K
gmywfk 7lm71t
14 Apr 23
Other Events
8:33am
8-K
we6vcy
10 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am